Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/PER-005-05
PER-005-05Completed未知

Randomized, double-blind, placebo-controlled, dose-range study to assess the safety and efficacy of oral TAK-715 in the treatment of signs and symptoms of rheumatoid arthritis

TAKEDA GLOBAL RESEARCH & DEVELOPMENT CENTER, INC.,0 sites0 target enrollmentStarted: April 6, 2005Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
未知
Status
Completed
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 to 0 (—)
Sex
All

Inclusion Criteria

  • •a) The patient is able to comply with the protocol and has signed the informed consent form
  • •b) The subject is a man or woman 18 years of age or older, diagnosed with rheumatoid arthritis
  • •c) Women who are able to conceive should not be pregnant or breastfeeding
  • •d) The patient must have undergone a physical examination that in the opinion of the researcher, does not demonstrate clinically significant abnormalities
  • •e) The patient must have laboratory tests whose results are normal or if abnormal, are not clinically significant
  • •f) The patient must have a normal electrocardiogram or if abnormal, it should not be clinically significant
  • •g) The patient should have a chest radiograph that shows no signs of active tuberculosis or clinically significant findings.
  • •h) The patient should have a negative skin test of the purified protein derivative (PPD)
  • •i) The patient must have been receiving methotrexate orally or parenterally for at least 6 months before and should receive a stable dose of methotrexate for at least 4 weeks before the baseline visit.
  • •j) In the selection and baseline visits, the patient must have at least 6 inflamed joints and 9 painful joints
  • •k) At the screening visit, the patient should have a CRP of at least 1.2 mg / dL or an ESR of at least 28 mm / hour.
  • •1) If a patient is taking a systemic corticosteroid, the maintenance dose of prednisone or its equivalent should remain stable for at least 4 weeks, may not exceed 10 mg / day and the patient should continue with that stable dose throughout the study.
  • •m) If a patient is taking an NSAID for the treatment of rheumatoid arthritis, the maintenance dose of NSAID should remain stable for at least 4 weeks before the baseline visit and the patient should continue with that stable dose throughout the study

Exclusion Criteria

  • •a) The patient has been diagnosed with any type of arthritis at 16 years of age or earlier.
  • •b) The patient has a clinically relevant history of disease.
  • •c) The patient has a known history of human immunodeficiency virus (HIV) infection.
  • •d) The patient has a known history of hepatitis B or C.
  • •e) The patient has uncontrolled hypertension.
  • •f) The patient has moderate or severe liver disease.
  • •g) The patient has a high serum creatinin
  • •h) The patient has a hemoglobin less than 9.0 mg / dL, a white blood cell count less than 3,000 / inn or a platelet count less than 100,000 / mm3
  • •i) The patient has a functional status IV for rheumatoid arthritis
  • •j) The patient has used an antirheumatic disease modifier drug (DMARD) or
  • •a biological agent other than methotrexate in the previous 8 weeks
  • •k) The patient has failed treatment due to lack of efficacy with any anti-TNF agent.
  • •l) The patient has failed due to lack of efficacy with more than 2 DMARDs m) The patient has received any intra-articular, intramuscular or intravenous corticosteroid within the previous 4 weeks
  • •n) The patient has received an alkylating agent.
  • •o) The patient has a high risk of opportunistic infection
  • •p) The patient has antecedents of, or a current inflammatory condition with signs and symptoms that could confuse the diagnosis of rheumatoid arthritis
  • •q) The patient has been diagnosed with secondary, non-inflammatory arthritis.
  • •r) The patient has a history of drug abuse within the past 2 years.
  • •s) The patient has a BMI greater than 35
  • •t) The patient has a previous history of cancer, other than basal cell carcinoma , which has not been in remission for at least 5 years before
  • •u) The patient does not want or is not able to comply with the protocol
  • •v) The patient can not understand written or spoken English or any other language in which a certified translation of the approved informed consent is available.
  • •w) The patient has known hypersensitivity to TAK-715 or its components.

Investigators

Similar Trials

Not yet recruiting
Not Applicable
A clinical trial that evaluates safety, tolerability, pharmacokinetics, and pharmacodynamic characteristics after oral administration of investigational product(AVI-CO-004Tab) 10 days to male volunteers with AIDSCertain infectious and parasitic diseases
KCT0005329Avixgen36
Completed
Unknown
Phase 1 clinical trial to evaluate the safety, tolerability, and pharmacokinetic properties of EB-203 eye drops in healthy adult volunteersDiseases of the eye and adnexa
KCT0008881Eyebiokorea28
Active, not recruiting
Not Applicable
Randomised, double-blind, placebo-controlled, dose-ranging Phase II study of APD421 (amisulpride for IV injection) for the prevention of post-operative nausea and vomitingPost-operative nausea and vomiting (PONV)MedDRA version: 14.1Level: LLTClassification code 10036901Term: Prophylaxis against postoperative nausea and vomitingSystem Organ Class: 10042613 - Surgical and medical procedures
EUCTR2011-004267-71-DEAcacia Pharma Ltd200
Active, not recruiting
Not Applicable
Double-blind, randomized, placebo-controlled, dose-finding, parallel-group study to assess the hemodynamic effects, clinical efficacy, tolerability and safety of Aviptadil (Vasoactive Intestinal Peptide) after single and repeated inhalation in patients with pulmonary arterial hypertension.Pulmonary arterial hypertension (PAH) due to idiopathic pulmonary arterial hypertension (IPAH), familial PAH or PAH associated with connective tissue diseases (CTD) (e.g. systemic sclerosis, systemic lupus erythematosus) or to repaired congenital heart defects (RCHD).MedDRA version: 9.1Level: LLTClassification code 10064911Term: Pulmonary arterial hypertensionMedDRA version: 9.1Level: LLTClassification code 10065151Term: Idiopathic pulmonary arterial hypertensionMedDRA version: 9.1Level: LLTClassification code 10065152Term: Familial pulmonary arterial hypertensionMedDRA version: 9.1Level: LLTClassification code 10065150Term: Associated with pulmonary arterial hypertension
EUCTR2007-003621-24-NLMondoGEN AG48
Active, not recruiting
Not Applicable
Double-blind, randomized, placebo-controlled, dose-finding, parallel-group study to assess the hemodynamic effects, clinical efficacy, tolerability and safety of Aviptadil (Vasoactive Intestinal Peptide) after single and repeated inhalation in patients with pulmonary arterial hypertension.
EUCTR2007-003621-24-BEMondoGEN AG48